Literature DB >> 12412948

An evidence-based clinical pathway for bronchiolitis safely reduces antibiotic overuse.

Stephen D Wilson1, Barbara B Dahl, Robert D Wells.   

Abstract

The overuse of antibiotics in the management of bronchiolitis is widely known, yet physician practice has been slow to change. We report here on the success of a clinical pathway in reducing antibiotic overuse in the inpatient management of bronchiolitis. The charts of 181 children admitted for bronchiolitis were reviewed to determine whether antibiotic use was reduced in patients managed using a clinical pathway compared with a matched group of patients managed without use of the pathway (non-pathway group). Only 9% of the pathway patients received antibiotics compared with 27% of the nonpathway group. No negative effects were seen on other quality measures including unplanned return for care. Furthermore, for patients managed using the clinical pathway, cost and length of stay were significantly reduced. Overall, the study suggests that implementation of a clinical pathway may be an effective means to change physician practice and reduce the unnecessary use of antibiotics, while maintaining or improving other aspects of quality of care.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12412948     DOI: 10.1177/106286060201700507

Source DB:  PubMed          Journal:  Am J Med Qual        ISSN: 1062-8606            Impact factor:   1.852


  9 in total

1.  Diagnostic performance of a rapid antigen test for RSV in comparison with a 19-valent multiplex RT-PCR ELISA in children with acute respiratory tract infections.

Authors:  Heike Schützle; Josef Weigl; Wolfram Puppe; Johannes Forster; Reinhard Berner
Journal:  Eur J Pediatr       Date:  2007-09-02       Impact factor: 3.183

Review 2.  Principles and strategies of antimicrobial stewardship in the neonatal intensive care unit.

Authors:  Sameer J Patel; Lisa Saiman
Journal:  Semin Perinatol       Date:  2012-12       Impact factor: 3.300

3.  Standardized Clinical Pathways for Hospitalized Children and Outcomes.

Authors:  K Casey Lion; Davene R Wright; Suzanne Spencer; Chuan Zhou; Mark Del Beccaro; Rita Mangione-Smith
Journal:  Pediatrics       Date:  2016-03-21       Impact factor: 7.124

4.  Nine Seasons of a Bronchiolitis Observation Unit and Home Oxygen Therapy Protocol.

Authors:  Timothy J D Ohlsen; Alexander M Knudson; E Kent Korgenski; David R Sandweiss; Michelle G Hofmann; Tiffany S Glasgow; Eric R Coon
Journal:  J Hosp Med       Date:  2021-05       Impact factor: 2.960

5.  The quality of the evidence base for clinical pathway effectiveness: room for improvement in the design of evaluation trials.

Authors:  Thomas Rotter; Leigh Kinsman; Erica James; Andreas Machotta; Ewout W Steyerberg
Journal:  BMC Med Res Methodol       Date:  2012-06-18       Impact factor: 4.615

6.  Understanding implementation processes of clinical pathways and clinical practice guidelines in pediatric contexts: a study protocol.

Authors:  Shannon D Scott; Jeremy Grimshaw; Terry P Klassen; Alberto Nettel-Aguirre; David W Johnson
Journal:  Implement Sci       Date:  2011-12-28       Impact factor: 7.327

7.  Effect of point of care information on inpatient management of bronchiolitis.

Authors:  W James King; Nicole Le Saux; Margaret Sampson; Isabelle Gaboury; Mark Norris; David Moher
Journal:  BMC Pediatr       Date:  2007-01-24       Impact factor: 2.125

8.  Impact of the implementation of an evidence-based guideline on diagnostic testing, management, and clinical outcomes for infants with bronchiolitis.

Authors:  Ricardo Henao-Villada; Monica P Sossa-Briceño; Carlos E Rodríguez-Martínez
Journal:  Ther Adv Respir Dis       Date:  2016-08-04       Impact factor: 4.031

9.  Assessing the appropriateness of paediatric antibiotic overuse in Australian children: a population-based sample survey.

Authors:  Gaston Arnolda; Peter Hibbert; Hsuen P Ting; Charli Molloy; Louise Wiles; Meagan Warwick; Tom Snelling; Nusrat Homaira; Adam Jaffe; Jeffrey Braithwaite
Journal:  BMC Pediatr       Date:  2020-04-24       Impact factor: 2.125

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.